West Pharmaceutical Services マネジメント
マネジメント 基準チェック /44
West Pharmaceutical Servicesの CEO はEric Greenで、 Apr2015年に任命され、 の在任期間は 11.25年です。 の年間総報酬は$ 7.19Mで、 16.4%給与と83.6%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.26%を直接所有しており、その価値は$ 58.91M 。経営陣と取締役会の平均在任期間はそれぞれ2.5年と9.8年です。
主要情報
Eric Green
最高経営責任者
US$7.2m
報酬総額
| CEO給与比率 | 16.37% |
| CEO在任期間 | 11.3yrs |
| CEOの所有権 | 0.3% |
| 経営陣の平均在職期間 | 2.5yrs |
| 取締役会の平均在任期間 | 9.8yrs |
経営陣の近況
Recent updates
Seeking Alpha • Jul 24
West Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shift
Summary West Pharmaceutical Services delivered a strong 2Q26, beating on both revenue ($872.3M, +13.8% YoY) and EPS ($2.37, +$0.29 vs. consensus). WST raised full-year guidance to $3.345–$3.380B in sales and $8.85–$9.05 in EPS, reflecting confidence in sustained double-digit organic growth and margin expansion. High-Value Product components and biologics drove mix shift, with HVP now 49% of revenue and biologics up 29% organically, supporting durable margin gains. Valuation remains rich at 41x forward earnings, but the premium is justified by high-quality compounding, visible growth pillars, and conservative guidance. Read the full article on Seeking Alpha
ナラティブ更新 • Jul 13
WST: GLP 1 Injectables And On Body Delivery Moves Will Shape Future Returns
The analyst price target for West Pharmaceutical Services has been raised from $358.79 to $379.00, as analysts cite updated models that reflect healthy sector trends, exposure to GLP-1 related volumes, and continued support from recent Outperform ratings and target increases across the Street. Analyst Commentary Recent research commentary on West Pharmaceutical Services has focused on how the company is positioned within injectable drug delivery, its exposure to GLP-1 related volumes, and expectations for execution against updated financial models ahead of upcoming earnings events.ナラティブ更新 • Jun 22
WST: Injectable Exposure And High Value Mix Will Shape Balanced Future Returns
Analysts have lifted their implied price target for West Pharmaceutical Services by about $6 to reflect updated fair value assumptions and ongoing confidence in injectable exposure, high value product momentum, and management execution highlighted in recent research. Analyst Commentary Recent research on West Pharmaceutical Services centers on how well the company is positioned in injectable markets and high value product categories, and how that ties into fair value and execution risk.ナラティブ更新 • Jun 06
WST: Injectable Platforms And High Value Mix Will Support Future Earnings Power
Analysts have nudged their fair value estimate for West Pharmaceutical Services higher to about $352 per share, citing refreshed price targets around $325 to $375 and continued confidence in injectable driven growth and execution. Analyst Commentary Recent Street research has focused on how West Pharmaceutical Services is executing on growth in injectables and high value product categories, and what that could mean for valuation as price targets shift higher.ナラティブ更新 • Apr 27
WST: Higher Margin Mix And Contract Services Expansion Will Support Earnings Power
Analysts have lifted the implied fair value estimate for West Pharmaceutical Services by about $11 to roughly $350, as a series of recent price target changes reflect updated assumptions around growth, margins and P/E multiples. Analyst Commentary Recent Street research on West Pharmaceutical Services shows a mix of upbeat and cautious messages as analysts recalibrate their models and price targets around updated assumptions for growth, margins and P/E multiples.ナラティブ更新 • Feb 07
WST: Margin Resilience And Drug Delivery Portfolio Shift Will Support Earnings Power
Analysts have trimmed their price target on West Pharmaceutical Services by about US$7. This reflects updated assumptions around slightly softer revenue growth, a modestly higher discount rate, a small adjustment to future P/E expectations, and a marginally stronger profit margin outlook.ナラティブ更新 • Jan 24
WST: 2026 Drug Delivery Focus And New Syringe Platform Will Support Earnings Power
Analysts have kept their fair value estimate for West Pharmaceutical Services steady at about $345.71 per share, with only slight tweaks to assumptions like the discount rate, long term revenue growth, profit margin, and future P/E, which together feed into their updated price target narrative. What's in the News West Pharmaceutical Services agreed to sell all manufacturing and supply rights for its SmartDose 3.5 mL On Body Delivery System, along with associated facilities, to AbbVie for total consideration of US$112.5 million at close, subject to working capital and other adjustments (Key Developments).ナラティブ更新 • Jan 07
WST: Normalizing Markets And 2026 Visibility Will Support Earnings Power
Narrative update The updated analyst price target for West Pharmaceutical Services reflects a largely steady fair value near US$346. Analysts point to recent target hikes, higher EPS estimates and a constructive view on growth drivers into 2026 as key supports for the current valuation framework.ナラティブ更新 • Dec 19
WST: Normalizing End Markets Will Support Stronger Earnings Base Into 2026
Analysts have modestly raised their price target on West Pharmaceutical Services to approximately $370, up from about $310. This reflects increased earnings estimates, a stronger setup into 2026, and improving, more stable end markets.ナラティブ更新 • Dec 05
WST: Normalizing End Markets Will Support Strong Earnings Base Into 2026
Analysts have nudged their price target for West Pharmaceutical Services slightly higher to approximately $370, reflecting increased confidence in the company’s earnings power and growth drivers as market conditions normalize and set up favorably into 2026. Analyst Commentary Analyst views on West Pharmaceutical Services remain broadly constructive, with recent target hikes reflecting growing conviction that the company can sustain its earnings recovery as end markets normalize into 2026.ナラティブ更新 • Nov 21
WST: Strong 2025 Outlook and Management Confidence Will Sustain Positive Momentum
West Pharmaceutical Services has seen its average analyst price target raised, with significant increases attributed to strong quarterly results, growing end market confidence, and a positive management outlook for 2026, according to analysts. Analyst Commentary Analysts have responded to West Pharmaceutical Services' recent performance and outlook with a range of observations tying directly to the company's valuation, execution, and growth prospects.ナラティブ更新 • Nov 07
WST: Sustained Earnings Momentum Will Drive Confidence Into 2026
West Pharmaceutical Services has seen its average analyst price target rise from approximately $321 to $351. Analysts cite continued growth drivers and improved market conditions following a strong quarterly performance.ナラティブ更新 • Oct 23
Analysts Raise Target for West Pharmaceutical Services Amid Strong Outlook and Upgraded Guidance
Analysts have increased their price target for West Pharmaceutical Services by $5 to $321. They cited the company's encouraging earnings call, management's confidence in future estimates, and stable end markets with improving investment sentiment.Seeking Alpha • Mar 11
West Pharmaceutical: Remains A Strong Long-Term Prospect
Summary West Pharmaceutical Services has faced a challenging year, underperforming against the index, with declining volumes, margins, and returns, but remains a strong long-term investment. The company's high-value products segment, driven by GLP-1 medications and biologics, is expected to boost margins and returns significantly. Despite poor timing in share buybacks and management concerns, West's valuation suggests a potential 12.8% annual return, making it a buy. Key risks include management's strategic decisions and valuation, but the worst seems behind, with attractive prices for long-term growth. Read the full article on Seeking AlphaSeeking Alpha • Feb 17
West Pharmaceuticals Takes A Plunge, But May Still Offer Opportunities
Summary The price of West Pharmaceutical Services plunged over 38% after it released its Q4 and FY 2024 earnings results on February 13. Shareholders, mostly institutional investors apparently, did not like the bottom-line results nor the uninspiring guidance for 2025. Still, West should not be overlooked, and there may be opportunities if the share price continues to rebound after a market overreaction. Read the full article on Seeking AlphaCEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$565m |
| Mar 31 2026 | n/a | n/a | US$543m |
| Dec 31 2025 | US$7m | US$1m | US$494m |
| Sep 30 2025 | n/a | n/a | US$492m |
| Jun 30 2025 | n/a | n/a | US$488m |
| Mar 31 2025 | n/a | n/a | US$467m |
| Dec 31 2024 | US$8m | US$1m | US$493m |
| Sep 30 2024 | n/a | n/a | US$500m |
| Jun 30 2024 | n/a | n/a | US$525m |
| Mar 31 2024 | n/a | n/a | US$569m |
| Dec 31 2023 | US$9m | US$1m | US$593m |
| Sep 30 2023 | n/a | n/a | US$559m |
| Jun 30 2023 | n/a | n/a | US$519m |
| Mar 31 2023 | n/a | n/a | US$552m |
| Dec 31 2022 | US$8m | US$1m | US$586m |
| Sep 30 2022 | n/a | n/a | US$631m |
| Jun 30 2022 | n/a | n/a | US$686m |
| Mar 31 2022 | n/a | n/a | US$684m |
| Dec 31 2021 | US$9m | US$1m | US$662m |
| Sep 30 2021 | n/a | n/a | US$613m |
| Jun 30 2021 | n/a | n/a | US$519m |
| Mar 31 2021 | n/a | n/a | US$423m |
| Dec 31 2020 | US$8m | US$989k | US$346m |
| Sep 30 2020 | n/a | n/a | US$312m |
| Jun 30 2020 | n/a | n/a | US$286m |
| Mar 31 2020 | n/a | n/a | US$261m |
| Dec 31 2019 | US$7m | US$936k | US$242m |
報酬と市場: Ericの 総報酬 ($USD 7.19M ) は、 US市場 ($USD 14.63M ) の同様の規模の企業の平均を下回っています。
報酬と収益: Ericの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Eric Green (56 yo)
11.3yrs
在職期間
US$7,190,876
報酬
Mr. Eric Mark Green serves as Independent Director at Ecolab Inc. since December 08, 2022. He has been the Chief Executive Officer of West Pharmaceutical Services, Inc. since April 24, 2015 and its Preside...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Non-Independent Chair of the Board | 11.3yrs | US$7.19m | 0.26% $ 58.9m | |
| Senior VP & CFO | less than a year | US$11.80m | 0.0042% $ 977.0k | |
| Chief HR Officer & Senior VP | 10.8yrs | US$1.39m | 0.024% $ 5.5m | |
| SVP & Chief Proprietary Segment Officer | 1.2yrs | US$2.40m | 0.00087% $ 200.9k | |
| VP of Finance & Chief Accounting Officer | 6.2yrs | データなし | 0.0022% $ 498.9k | |
| Senior VP & CTO | less than a year | データなし | データなし | |
| Vice President of Investor Relations | no data | データなし | データなし | |
| Senior VP | less than a year | データなし | データなし | |
| Vice President of Global Communications | no data | データなし | データなし | |
| Senior Vice President of Strategy & Corporate Development | 2.7yrs | データなし | 0.00080% $ 184.8k | |
| Senior VP and Chief Quality & Regulatory Officer | 4.2yrs | データなし | データなし | |
| President of Contract Manufacturing | 2.3yrs | データなし | データなし |
2.5yrs
平均在職期間
56yo
平均年齢
経験豊富な経営陣: WSTの経営陣は 経験豊富 であると考えられます ( 2.5年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Non-Independent Chair of the Board | 11.2yrs | US$7.19m | 0.26% $ 58.9m | |
| Independent Director | 12.4yrs | US$344.94k | 0.025% $ 5.7m | |
| Lead Independent Director | 6.4yrs | US$353.84k | 0.0067% $ 1.5m | |
| Independent Director | 1.6yrs | US$330.94k | 0.0019% $ 434.2k | |
| Independent Director | 15.4yrs | US$344.94k | 0.062% $ 14.3m | |
| Independent Director | 15.4yrs | US$329.94k | 0.065% $ 15.0m | |
| Independent Director | 9.8yrs | US$332.14k | 0.016% $ 3.6m | |
| Independent Director | 4yrs | US$329.94k | 0.0039% $ 896.2k | |
| Independent Director | 14.4yrs | US$329.94k | 0.045% $ 10.4m | |
| Independent Director | 9.1yrs | US$334.94k | データなし | |
| Honorary Director | no data | データなし | データなし | |
| Independent Director | 4.9yrs | US$343.84k | 0.0051% $ 1.2m |
9.8yrs
平均在職期間
65yo
平均年齢
経験豊富なボード: WSTの 取締役会 は 経験豊富 であると考えられます ( 9.8年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/27 16:26 |
| 終値 | 2026/07/24 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
West Pharmaceutical Services, Inc. 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。27
| アナリスト | 機関 |
|---|---|
| Luke Sergott | Barclays |
| Lawrence Marsh | Barclays |
| Curtis Moiles | BNP Paribas |